News
-
-
PRESS RELEASE
Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price
Telomir Pharmaceuticals, Inc. raises $1 million in equity funding through The Starwood Trust, reinforcing financial strength. Telomir-1 shows transformative potential in addressing age-related conditions -
-
PRESS RELEASE
Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1
Telomir Pharmaceuticals announces groundbreaking preclinical results showcasing Telomir-1's efficacy in reversing key parameters of Type 2 diabetes mellitus, potentially addressing insulin resistance at its root -
-
PRESS RELEASE
Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Telomir Pharmaceuticals announces groundbreaking preclinical results confirming the efficacy of Telomir-1 in age-reversal science. The study demonstrates significant age-reversal effects in model organisms, supporting longevity and improved healthspan -
-
PRESS RELEASE
Telomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of Longevity on Health Uncensored With Dr. Drew on the Fox Business Network This Sunday
Telomir Pharmaceuticals to feature on Health Uncensored with Dr. Drew on Fox Business Network, discussing Telomir-1 and longevity science -
-
PRESS RELEASE
Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications
Telomir Pharmaceuticals, Inc. appoints Dr. Itzchak Angel as Chief Scientific Advisor to lead developments in longevity science and advance Telomir-1 small molecule for age-related conditions in humans and animals
